Bristol-Myers Squibb (BMY), seeking to re-energize its cancer pipeline, is turning to an artificial intelligence startup for help, inking a deal to use the firm’s analytical tools and “real-world” patient data to better target and accelerate clinical trials.
The deal with Concerto HealthAI, a Boston-based firm backed by the $1 billion SymphonyAI fund, is an effort to infuse real-world evidence from medical practices across the U.S. into Bristol’s research. Concerto uses data from CancerLinQ, a national repository of information on cancer patients, to search for patterns that may inform drug development.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
